In the previous pivotal clinical trial of anti-CD19 CAR T-cell therapy for r/r DLBCL, patients with RT were not included because RT is regarded as a distinct disease entity [79,80]. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.